Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy
Nicolas Gazeau(Centre Hospitalier Universitaire de Lille), Jordan Gauthier(Seattle Cancer Care Alliance), Damian J. Green(Sylvester Comprehensive Cancer Center), Valentin Ortiz-Maldonado(Hospital Clínic de Barcelona), David G. Maloney(Fred Hutch Cancer Center), Andrew J. Cowan(University of Washington Medical Center), Eneida R. Nemecek(Oregon Health & Science University), Pere Barba(Universitat Autònoma de Barcelona), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Antonio Pérez‐Martínez(Hospital Universitario La Paz), Alexandre V. Hirayama(University of Washington), Mi Kwon(Hospital General Universitario Gregorio Marañón), Mazyar Shadman(University of Washington), Rafael Hernani(Hospital Clínico Universitario de Valencia), Lucía López‐Corral(Instituto de Investigación Biomédica de Salamanca), Staci Williamson(Oregon Health & Science University), Rebeca Bailén(Hospital General Universitario Gregorio Marañón), Jessie Myers(Oregon Health & Science University), Richard T. Maziarz(Oregon Health & Science University), Victor A. Chow(Whipps Cross University Hospital), Juan Luis Reguera(Instituto de Biomedicina de Sevilla), Cameron J. Turtle(The University of Sydney), Alexandria Hodges Dwinal(Oregon Health & Science University)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k